Loading
Every dated change on the records linked to Thyroid cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Objective response 64 percent after platinum chemotherapy and 85 percent in previously untreated RET fusion-positive non-small-cell lung cancer; intracranial response 91 percent.
A milestone in how this cancer is treated.
Radioiodine-refractory differentiated thyroid cancer
3-year event-free 95.
A milestone in how this cancer is treated.
Advanced medullary thyroid cancer
RET-fusion NSCLC and thyroid; RET-mutant MTC
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
ORR 56%; median OS 15 months.
A milestone in how this cancer is treated.
Cometriq for medullary thyroid cancer; 21 Mar 2014. Cabometyx (RCC) Sep 2016
With trametinib: BRAF V600E/K metastatic melanoma; later adjuvant melanoma, BRAF V600E NSCLC, anaplastic thyroid cancer, tumour-agnostic solid tumours and paediatric low-grade glioma
With dabrafenib: metastatic melanoma; later adjuvant melanoma, NSCLC, anaplastic thyroid cancer, tumour-agnostic BRAF V600E solid tumours, paediatric low-grade glioma
Radioiodine-refractory differentiated thyroid cancer
PFS 10.
A milestone in how this cancer is treated.
Medullary thyroid cancer (Cometriq)
Cabozantinib lengthened progression-free survival compared with placebo in progressive medullary thyroid cancer; approved in November 2012.
Ablation success 85.
Vandetanib prolonged progression-free survival over placebo in advanced medullary thyroid cancer; approved in April 2011 as the first drug for the disease.
A milestone in how this cancer is treated.
First therapeutic use in thyroid cancer (Seidlin); formal approval followed
Seidlin, Marinelli, and Oshry: the first theranostic.
A milestone in how this cancer is treated.